Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers

Read the full article See related articles

Discuss this preprint

Start a discussion

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Alzheimer’s disease (AD) develops over a prolonged asymptomatic phase marked by silent pathology. Identifying cognitively unimpaired individuals likely to progress to mild cognitive impairment (MCI) is essential for early intervention. We investigated whether multimodal combinations of biomarkers, including frequency-specific neurophysiological activity, enhance prediction beyond demographic and genetic factors in older adults (n = 102; 31 progressors; mean follow-up = 5.9 years). Biomarkers included MEG-derived alpha power, MRI-derived hippocampal volume, plasma Aβ42/40 ratio and p-tau217, and neocortical Aβ and entorhinal tau PET. Cox regression models estimated progression risk and tested time-varying prognostic effects. Neurophysiological and proteinopathy biomarkers improved prediction beyond clinical and genetic factors. Elevated alpha power predicted short-term risk, but its predictive value weakened over time, whereas high neocortical Aβ became increasingly predictive with longer follow-up. Plasma Aβ42/40, p-tau217, and tau PET each conferred higher risk, while hippocampal volume did not. Findings support a multimodal, time-sensitive framework for individualized risk prediction in preclinical AD.

Article activity feed